MAP2K7 and lung cancer: As a result, the combination treatment of NVP-BEZ235 (PI3K inhibitor) and ARRY-142886 (MEK Inhibitor) [117] showed significant tumor suppression in KRASG12D lung cancer cells, whereas ARRY-142886 alone exerted mild effect [98].